{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:05:56Z","timestamp":1789628756525,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.jns.2014.01.035","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T09:15:40Z","timestamp":1391505340000},"page":"223-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab"],"prefix":"10.1016","volume":"339","author":[{"given":"Joanna","family":"Kitley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Evangelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"K\u00fcker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2014.01.035_bb0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.01.035_bb0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-003-0979-2","article-title":"A case of relapsing neuromyelitis optica treated with glatiramer acetate","volume":"250","author":"Bergamaschi","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2014.01.035_bb0015","doi-asserted-by":"crossref","first-page":"e33878","DOI":"10.1371\/journal.pone.0033878","article-title":"White matter atrophy and cognitive dysfunctions in neuromyelitis optica","volume":"7","author":"Blanc","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2014.01.035_bb0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archneurol.2007.16","article-title":"Cognitive functions in neuromyelitis optica","volume":"65","author":"Blanc","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.01.035_bb0025","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/1352458508092810","article-title":"Early relapses after the first dose of natalizumab in active multiple sclerosis patients","volume":"14","author":"Centonze","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.01.035_bb0030","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","author":"Elsone","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.01.035_bb0035","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/j.1468-1331.2007.01807.x","article-title":"Relapsing neuromyelitis optica responsive to glatiramer acetate treatment","volume":"14","author":"Gartzen","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2014.01.035_bb0040","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/WNL.0b013e31826845fe","article-title":"Does natalizumab therapy worsen neuromyelitis optica?","volume":"79","author":"Jacob","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.01.035_bb0045","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","article-title":"Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells","volume":"72","author":"Kivisakk","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.01.035_bb0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.01.035_bb0055","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","article-title":"Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis","volume":"71","author":"Krumbholz","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.01.035_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.01.035_bb0065","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.01.035_bb0070","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000302687","article-title":"Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells","volume":"63","author":"Putzki","year":"2010","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jns.2014.01.035_bb0075","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/archneurol.2011.194","article-title":"Lack of response to monoclonal antibody therapy in neuromyelitis optica","volume":"68","author":"Qian","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.01.035_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.23721","article-title":"Cognitive impairment and cortical degeneration in neuromyelitis optica","volume":"73","author":"Saji","year":"2013","journal-title":"Ann Neurol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14000598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14000598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:43:05Z","timestamp":1758382985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X14000598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":16,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0022510X14000598"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.01.035","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}